Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial

Diabetes, Obesity & Metabolism
Ryuzo KawamoriJyothis George

Abstract

This double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as add-on to linagliptin (Lina) 5 mg (fixed-dose combination, Empa/Lina 10/5 or 25/5) in insufficiently controlled Japanese type 2 diabetes patients. The trial (40 sites; May 2015-March 2017) involved screening 433 adults (≥20 years) who were treatment-naive or were using one oral antidiabetic drug for ≥12 weeks, which was discontinued at enrolment. Patients with HbA1c 7.5%-10.0% after ≥16 weeks of using Lina (pre-enrolment or during a 16-week, open-label period) and 2 weeks of using placebo (Plc) for Empa/Lina 10/5, plus Lina, were randomized (2:1) to once-daily Empa/Lina 10/5 (n = 182) or Plc/Lina 10/5 (n = 93) for 24 weeks. Patients with HbA1c ≥ 7.0% at Week 24 received Empa/Lina up-titrated to 25/5 (n = 126) or the corresponding placebo (n = 80), per randomization, from Week 28; 172 Empa/Lina and 84 Plc/Lina patients completed 52 weeks. Change from baseline in HbA1c was greater (P < .0001) with Empa/Lina than with Plc/Lina at Week 24 (primary outcome, -0.93% vs 0.21%; adjusted mean difference, -1.14%) and Week 52 (-1.16% vs 0.06%; adjusted mean difference, -1.22%). Mo...Continue Reading

References

Nov 27, 2004·Diabetes Research and Clinical Practice·Mitsuo FukushimaYutaka Seino
May 28, 2009·JAMA : the Journal of the American Medical Association·Juliana C N ChanFrank B Hu
Aug 17, 2011·Diabetes, Obesity & Metabolism·D D'Alessio
Sep 19, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas RauchTim Heise
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Mar 18, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nikolaus MarxHans-Juergen Woerle
Jul 16, 2015·Clinical and Experimental Pharmacology & Physiology·Xiao-Wu ChenShu-Feng Zhou
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 15, 2016·Current Diabetes Reviews·Matthew J Levine
Nov 9, 2016·Vascular Health and Risk Management·James W Reed
Dec 28, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Kohei KakuUNKNOWN EMPA-REG OUTCOME® Investigators
Nov 29, 2016·Diabetology International·UNKNOWN Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with DiabHideki Ito

❮ Previous
Next ❯

Citations

May 7, 2020·Advances in Therapy·Ona Kinduryte SchorlingHristo Iliev
Jul 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tomoho NodaMasamitsu Nakazato
Aug 4, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lidan YangZhenmei An

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
amputation
amputations

Clinical Trials Mentioned

NCT02453555
NCT01243424
NCT01897532

Software Mentioned

SAS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.